Companies › Cinclus Pharma Holding
1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Gastroenterology; next expected readout Nov 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Linaprazan glurate Potassium-competitive acid blocker (P-CAB); H+/K+-ATPase inhibitor | ATP4A | Phase 3 | GERD (Gastroesophageal Reflux Disease); Pharmacokinetics | Nov 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07037875 | Linaprazan glurate | Phase 3 | GERD (Gastroesophageal Reflux Disease) | Gastroenterology | Sep 2026 |
| NCT05469854 | Linaprazan glurate | Phase 1 | Pharmacokinetics | Gastroenterology | Nov 2026 |
Phathom Pharmaceuticals Il-Yang Pharm. Carnot Laboratories AstraZeneca
Carnot Laboratories Phathom Pharmaceuticals Elgan Pharma Norgine Green Cross Wellbeing
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.